We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.31% | 1,641.00 | 1,640.50 | 1,641.00 | 1,656.00 | 1,635.00 | 1,642.00 | 3,262,013 | 16:07:50 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.77 | 67.85B |
From Apr 2019 to Apr 2024
TIDMGSK
RNS Number : 5891F
GlaxoSmithKline PLC
28 July 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
Hot Features
Premium
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================
a) Name Sir Andrew Witty
=== ======================== ============================================
b) Position/status CEO
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Sale of Ordinary Shares on 27 July 2016
transaction at a price of GBP16.9350.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP16.9350 10,000
------------ ----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2016-07-27
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================
a) Name Mr D S Redfern
=== ======================== ============================================
b) Position/status Chief Strategy Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the The exercise of options over 26,800 Ordinary
transaction Shares, granted on 20 February 2007 under
the GlaxoSmithKline Share Option Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP14.88 26,800
---------- ----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2016-07-27
=== ======================== ============================================
f) Place of the n/a
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== =========================================================================
a) Name Mr D S Redfern
=== ======================== ===============================================
b) Position/status Chief Strategy Officer
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===============================================
b) Nature of the The sale of 26,800 Ordinary Shares following
transaction the exercise of options granted on 20 February
2007 under the GlaxoSmithKline Share Option
Plan.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------- ----------
GBP16.942 26,800
----------- ----------
=== ======================== ===============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===============================================
e) Date of the transaction 2016-07-27
=== ======================== ===============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================
a) Name Mr D S Redfern
=== ======================== ============================================
b) Position/status Chief Strategy Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the The exercise of options over 24,186 Ordinary
transaction Shares, granted on 19 February 2008 under
the GlaxoSmithKline Share Option Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP11.47 24,186
---------- ----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2016-07-27
=== ======================== ============================================
f) Place of the n/a
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr D S Redfern
=== ======================== ==============================================
b) Position/status Chief Strategy Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The sale of 24,186 Ordinary Shares following
transaction the exercise of options granted on granted
on 19 February 2008 under the GlaxoSmithKline
Share Option Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------- ----------
GBP16.938 24,186
----------- ----------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2016-07-27
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================
a) Name Mr D S Redfern
=== ======================== ============================================
b) Position/status Chief Strategy Officer
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the The exercise of options over 2,614 Ordinary
transaction Shares, granted on 19 February 2008 under
the GlaxoSmithKline Share Option Plan.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ---------- ----------
GBP11.47 2,614
---------- ----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2016-07-28
=== ======================== ============================================
f) Place of the n/a
transaction
=== ======================== ============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ========================================================================
a) Name Mr D S Redfern
=== ======================== ==============================================
b) Position/status Chief Strategy Officer
=== ======================== ==============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ==============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ==============================================
b) Nature of the The sale of 2,614 Ordinary Shares following
transaction the exercise of options granted on granted
on 19 February 2008 under the GlaxoSmithKline
Share Option Plan.
=== ======================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------- ----------
GBP17.035 2,614
----------- ----------
=== ======================== ==============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ==============================================
e) Date of the transaction 2016-07-28
=== ======================== ==============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ======================================================================
a) Name Ms C Thomas
=== ======================== ============================================
b) Position/status Senior Vice President, Human Resources
=== ======================== ============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ======================== ============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ============================================
b) Nature of the Sale of Ordinary Shares on 28 July 2016
transaction at a price of GBP16.9757.
=== ======================== ============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ------------ ----------
GBP16.9757 43,000
------------ ----------
=== ======================== ============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ============================================
e) Date of the transaction 2016-07-28
=== ======================== ============================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ============================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDVLFLQDFFBBK
(END) Dow Jones Newswires
July 28, 2016 13:22 ET (17:22 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
